NZ706067A - Modulators of androgen synthesis - Google Patents

Modulators of androgen synthesis

Info

Publication number
NZ706067A
NZ706067A NZ706067A NZ70606713A NZ706067A NZ 706067 A NZ706067 A NZ 706067A NZ 706067 A NZ706067 A NZ 706067A NZ 70606713 A NZ70606713 A NZ 70606713A NZ 706067 A NZ706067 A NZ 706067A
Authority
NZ
New Zealand
Prior art keywords
modulators
androgen synthesis
androgen production
compositions
androgen
Prior art date
Application number
NZ706067A
Other languages
English (en)
Inventor
Gregory Alan Stoloff
Suzanne Jane Dilly
Paul Christopher Taylor
Original Assignee
Tangent Reprofiling Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tangent Reprofiling Ltd filed Critical Tangent Reprofiling Ltd
Publication of NZ706067A publication Critical patent/NZ706067A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NZ706067A 2012-09-26 2013-09-26 Modulators of androgen synthesis NZ706067A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705790P 2012-09-26 2012-09-26
US201361871662P 2013-08-29 2013-08-29
PCT/EP2013/070106 WO2014049071A1 (en) 2012-09-26 2013-09-26 Modulators of androgen synthesis

Publications (1)

Publication Number Publication Date
NZ706067A true NZ706067A (en) 2016-07-29

Family

ID=49293617

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ706067A NZ706067A (en) 2012-09-26 2013-09-26 Modulators of androgen synthesis

Country Status (14)

Country Link
US (4) US9072743B2 (cg-RX-API-DMAC7.html)
EP (1) EP2900270B1 (cg-RX-API-DMAC7.html)
JP (2) JP6434410B2 (cg-RX-API-DMAC7.html)
CN (1) CN104797271B (cg-RX-API-DMAC7.html)
AU (2) AU2013322612B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015006727B1 (cg-RX-API-DMAC7.html)
CA (1) CA2886132C (cg-RX-API-DMAC7.html)
ES (1) ES2734554T3 (cg-RX-API-DMAC7.html)
HK (1) HK1211868A1 (cg-RX-API-DMAC7.html)
IL (2) IL237892B (cg-RX-API-DMAC7.html)
MX (1) MX367782B (cg-RX-API-DMAC7.html)
NZ (1) NZ706067A (cg-RX-API-DMAC7.html)
PL (1) PL2900270T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014049071A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2900270T3 (pl) 2012-09-26 2019-09-30 Tangent Reprofiling Limited Połączenie benzo(izo)oksazolopiperydyn ze sprzężonym kwasem linolowym
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
AU2015257594A1 (en) * 2014-05-09 2016-11-24 Tangent Reprofiling Limited Modulators of androgen synthesis
CA3049980A1 (en) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
CA3059348A1 (en) 2017-04-11 2018-10-18 Regeneron Pharmaceuticals, Inc. Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family
AU2018348195B2 (en) 2017-10-11 2025-05-15 Regeneron Pharmaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
MY207352A (en) 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
JPH05502217A (ja) * 1989-08-21 1993-04-22 ベス イスラエル ホスピタル アソシエーション セロトニン拮抗薬の局所用調製物を使用した、皮膚、眼、および粘膜の過敏症、炎症、および過増殖状態の治療のための方法および組成物
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6319950B1 (en) 1997-02-18 2001-11-20 Michael C. Seidel Suppression of carcinoma using high purity conjugated linoleic acid (CLA)
JPH1192343A (ja) * 1997-09-22 1999-04-06 Shiseido Co Ltd 毛髪成長期延長剤
JPH11209279A (ja) * 1998-01-05 1999-08-03 Natural Ltd As 体重減少および肥満処置の方法
IL139975A0 (en) 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US6977271B1 (en) * 2001-08-30 2005-12-20 Health Research, Inc. Method for inhibition of angiogenesis and vasculogenesis
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
EP1480629A1 (en) * 2002-02-08 2004-12-01 Abbott Laboratories Combination therapy for treatment of schizophrenia
WO2004103262A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells
WO2005066196A1 (en) 2003-12-30 2005-07-21 Ranbaxy Laboratories Limited Amorphous form of finasteride and processes for its preparation
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
EP1890700A2 (en) * 2005-05-31 2008-02-27 Orexigen Therapeutics, Inc. Methods and compositions for managing psychotic disorders
WO2008034129A2 (en) * 2006-09-15 2008-03-20 Cornell Research Foundation Inc. Treatment of cancer or obesity with conjugated linoleic acids
US8420624B2 (en) * 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
AR070313A1 (es) 2008-01-03 2010-03-31 Gador Sa Un procedimiento para preparar una forma solida y cristalina de dutasteride, una forma polimorfica del compuesto (forma iii) y una composicion farmaceutica que incluye dicha forma
DK2280928T3 (en) * 2008-05-01 2018-11-05 Complexa Inc Vinyl-substituted fatty acids
CN101366705B (zh) * 2008-09-28 2010-09-08 浙江大学 利培酮透皮吸收贴片
US8420077B2 (en) 2009-04-20 2013-04-16 Allergan, Inc. Silk fibroin hydrogels and uses thereof
WO2012026663A1 (ko) * 2010-08-25 2012-03-01 이화여자대학교 산학협력단 운데실렌산, 공액리놀레산 및/또는 공액리놀레산 이성질체를 포함하는 항암보조제
EP2907504B1 (en) * 2011-02-08 2017-06-28 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
WO2014027973A1 (en) * 2012-08-14 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Paliperidone oral solution
PL2900270T3 (pl) 2012-09-26 2019-09-30 Tangent Reprofiling Limited Połączenie benzo(izo)oksazolopiperydyn ze sprzężonym kwasem linolowym
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
AU2015257594A1 (en) 2014-05-09 2016-11-24 Tangent Reprofiling Limited Modulators of androgen synthesis

Also Published As

Publication number Publication date
BR112015006727A2 (pt) 2017-07-04
IL237892A0 (en) 2015-05-31
AU2017221819A1 (en) 2017-09-21
CA2886132C (en) 2023-03-21
US20180064713A1 (en) 2018-03-08
AU2013322612A2 (en) 2015-04-09
CA2886132A1 (en) 2014-04-03
US9585887B2 (en) 2017-03-07
US20150258095A1 (en) 2015-09-17
JP2019052159A (ja) 2019-04-04
AU2013322612B2 (en) 2017-06-01
BR112015006727A8 (pt) 2019-08-27
WO2014049071A1 (en) 2014-04-03
IL266446A (en) 2019-06-30
JP6734346B2 (ja) 2020-08-05
US9808462B2 (en) 2017-11-07
JP2015532920A (ja) 2015-11-16
AU2013322612A1 (en) 2015-04-09
CN104797271A (zh) 2015-07-22
EP2900270B1 (en) 2019-03-06
AU2017221819B2 (en) 2019-05-02
EP2900270A1 (en) 2015-08-05
JP6434410B2 (ja) 2018-12-05
MX367782B (es) 2019-09-04
BR112015006727B1 (pt) 2022-08-16
ES2734554T3 (es) 2019-12-10
PL2900270T3 (pl) 2019-09-30
US9072743B2 (en) 2015-07-07
US20170189407A1 (en) 2017-07-06
US20140088120A1 (en) 2014-03-27
IL237892B (en) 2019-05-30
CN104797271B (zh) 2020-03-06
HK1211868A1 (en) 2016-06-03
MX2015003899A (es) 2015-11-25

Similar Documents

Publication Publication Date Title
PH12015501720B1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12015500180A1 (en) Compounds that are s1p modulating agents and/or atx modulating agents
IL238266A0 (en) Compositions for modulation of c9orf72 expression
IN2015DN00438A (cg-RX-API-DMAC7.html)
IN2014DN09085A (cg-RX-API-DMAC7.html)
PH12014502704A1 (en) Compounds and compositions for modulating egfr activity
MY172156A (en) Modulators of methyl modifying enzymes, compositions and uses thereof
EP3055414A4 (en) Compositions for modulating c9orf72 expression
AP2014008100A0 (en) Compositions and methods for modulating hemoglobingene family expression
IN2015DN03029A (cg-RX-API-DMAC7.html)
EP2855500A4 (en) METHOD AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION
GB2498325A (en) Modulation neural pathways
MX364069B (es) Moduladores de la proteína activadora de 5-lipoxigenasa.
AU2012270029A8 (en) Compositions and methods for modulating a kinase
MX2015002487A (es) Proceso para la preparacion de teneligliptina.
MX2015003899A (es) Modulares de la sintesis de andrógenos.
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
IN2014DN08496A (cg-RX-API-DMAC7.html)
EP3052634A4 (en) Compositions and methods for modulating biomass productivity
GEP201706626B (en) Synthesis of (s)-nifuratel
EA026371B8 (ru) Индолкарбонитрилы в качестве модуляторов рецептора андрогенов
IN2014DN11078A (cg-RX-API-DMAC7.html)
IN2015DN00725A (cg-RX-API-DMAC7.html)
IN2014DN07989A (cg-RX-API-DMAC7.html)
EP2888872A4 (en) INTEGRATED LASER AND MODULATOR TRANSMITTER FOR CABLE TELEVISION APPLICATIONS

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2018 BY OLCOTT INTERANTIONAL

Effective date: 20170903

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2019 BY OLCOTT INTERANTIONAL

Effective date: 20180906

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2020 BY OLCOTT INTERNATIONAL + CO., LLC

Effective date: 20190724

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2021 BY CPA GLOBAL

Effective date: 20200813

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2022 BY CPA GLOBAL

Effective date: 20210819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2023 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20220919

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2024 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20230918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2025 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20240917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2026 BY DENNEMEYER + CO

Effective date: 20260317